Experienced medical executive advances to permanent role following successful leadership as Interim CMOSEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026…
HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal…
Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy aloneElraglusib…
-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY® launch acceleration continues, supporting multi-billion-dollar potential-…
– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and…
Counterpart continues to demonstrate that unified data and real-time insights, delivered directly into the clinician’s workflow, drive measurable clinical and…
Guides year-end 2026 health plan membership range of 290,000 to 296,000. Announces its expectation that consensus adjusted EBITDA of approximately $145 million…
– Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of…
Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules ALPHARETTA, Ga., Jan. 12,…
Bitopertin was awarded the Commissioner’s National Priority Review Voucher (CNPV) and NDA is currently under FDA reviewUpdated data from the…